However, individual reports for some targeted agents, support an association between improved clinical outcomes such as PFS, OS or quality of life and certain AEs (e.g. skin toxicity with EGFR inhibitors and hypertension with VEGF inhibitors)14,15. This evidence concerns the gene EGFR and hypertensive disorder.